Xilio Therapeutics (XLO) Cash from Operations (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Cash from Operations data on file, last reported at 22343000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 177.1% year-over-year to 22343000.0; the trailing twelve-month figure through Mar 2026 stood at 56313000.0 (down 366.86% YoY), and the FY2025 full-year result was 4992000.0, up 72.84% from the prior year.
• Cash from Operations fell to 22343000.0 in Q1 2026, from 1998000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 28978000.0 in Q1 2025 to a low of 25250000.0 in Q1 2023.
• A 5-year average of 11179764.71 and a median of 14477000.0 in 2025 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations soared 375.93% in 2025 and tumbled 177.1% in 2026, its largest moves.
• Tracing XLO's Cash from Operations over 5 years: stood at 18223000.0 in 2022, then rose by 26.32% to 13427000.0 in 2023, then decreased by 5.44% to 14157000.0 in 2024, then jumped by 85.89% to 1998000.0 in 2025, then slumped by 1018.27% to 22343000.0 in 2026.
• Business Quant data shows XLO's Cash from Operations at 22343000.0 in Q1 2026, 1998000.0 in Q4 2025, and 17495000.0 in Q3 2025.